DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Abstract
Although chemotherapies kill most cancer cells, stem cell–enriched survivors seed metastasis, particularly in triple-negative breast cancers (TNBC). TNBCs arise from and are enriched for tumor stem cells. Here, we tested if inhibition of DOT1L, an epigenetic regulator of normal tissue stem/progenitor populations, would target TNBC stem cells.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 07, 2022
- Source ID
- 10.1158/1078-0432.ccr-21-1299
Entities
People
- Andrew J Ewald
- Apsra Nasir
- Claes Wahlestedt
- Derek Van Booven
- Diana J. Azzam
- Gray Pearson
- Hetakshi Kurani
- Joyce M Slingerland
- Kuzhuvelil B Harikumar
- Matthew Dunworth
- Seyedeh Fatemeh Razavipour
- Zhiqun Zhou
Organizations
- Congressionally Directed Medical Research Programs
- Florida International University
- Georgetown University
- Johns Hopkins School of Medicine
- Johns Hopkins University
- Leonard M. Miller School of Medicine
- Rajiv Gandhi Centre for Biotechnology
- The Breast Cancer Research Foundation
- University of Miami